Cationic Nanoparticles for Glioblastoma Treatment
Author Information
Author(s): Aslan Tuğba Nur
Primary Institution: Necmettin Erbakan University
Hypothesis
Can cationic micelle-like nanoparticles effectively deliver methotrexate for glioblastoma treatment?
Conclusion
The study found that cationic nanoparticles improved the anticancer efficacy of methotrexate on glioblastoma cells while reducing toxicity to normal cells.
Supporting Evidence
- Max incorporation efficiency of 89.5% was achieved for 25 µg/mL of methotrexate-loaded nanoparticles.
- The cumulative amount of methotrexate released reached 40% at physiological pH and 85% at a pH of 5.0 up to 12 hours.
- IC50 concentration of nanoparticles reduced cell viability to 49% in U87 and 72% in L929 cells.
- Cellular uptake of nanoparticles was found to be 1.92-fold higher in U87 than in L929 cells.
- Total apoptosis percentage in U87 cells was ~10-fold higher than in L929 cells.
- Nanoparticles inhibited cell motility and prevented metastasis of U87 cell lines.
Takeaway
Scientists created tiny particles that can carry medicine directly to brain cancer cells, helping to treat the cancer better while hurting healthy cells less.
Methodology
The study involved synthesizing magnetic iron oxide nanoparticles, incorporating methotrexate, and testing their effects on cancer and normal cells.
Limitations
In vivo investigations are necessary to confirm the system’s safety and effectiveness in more complex biological environments.
Participant Demographics
U87 cancer cells and L929 normal cells were used for testing.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website